Age and PSA level at diagnosis | Mean (range) |
Age (years) | 69.9 (47 - 86) |
PSA (initial, ng/mL) | 666.1 (24.25 - 6334) |
Clinical characteristics | Number of patients (%) |
ISUP grade group | 63 (92.6) |
1 | 5 (7.9) |
2 | 8 (12.7) |
3 | 15 (23.8) |
4 | 14 (22.2) |
5 | 21 (33.3) |
Paralysis (6 paraplegia* + 1 tetraplegia) | 7 (10.3) |
Hydronephrosis | 11 (16.2) |
Hypertension | 15 (22.1) |
Diabetes | 4 (5.9) |
Patients’ evolution |
|
Follow-up data | Mean (range) |
Follow-up duration (months) | 22.1 (3 - 99) |
PSA (nadir, ng/mL) | 22.5 (0.01 - 220.25) |
Time to nadir PSA level | 8.9 (3 - 57) |
PSA kinetics and deaths | Number of patients (%) |
PSA < 4 ng/mL in ≤ 12 months | 16 (23.6) |
Deaths | 19 (27.9) |